Wednesday, March 29, 2023 | Back issues
Courthouse News Service Courthouse News Service

Drug Patents

A federal court in California refused to dismiss a False Claims Act suit that claims pharmaceutical companies Allergan and Adamas misled the U.S. Patent Office into issuing “invalid” patents protecting Alzheimer’s drugs Namenda XR and Namzaric, which allegedly allowed the companies to have a monopoly.

SAN FRANCISCO — A federal court in California refused to dismiss a False Claims Act suit that claims pharmaceutical companies Allergan and Adamas misled the U.S. Patent Office into issuing invalid patents protecting Alzheimer’s drugs Namenda XR and Namzaric, which allegedly allowed the companies to have a monopoly. 

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading...